A Medscape article that might interest you.

[Guest guest]

Subject: Fwd: A Medscape article that might interest you.

Hi, Everyone....I found the full article did not go through the first time.

Blame me for lack of computer skills!!! Here's the full article....it's

very interesting for those of you who deal with the drug issues. Take

care, Everyone.

Margaret

[Guest guest]

The link is missing here.

<<I thought you might be interested in this.

ha! who are they kidding? this is a move toward 4th reichism. the bums.

To access the article, click on this Web address, or cut and paste it into a

browser window.

This article notification service provided by http://www.medscape.com>>

[Guest guest]

Dear ,

What is the title?

Suzy

>From: stinky72001@...

>Reply-SSRI medications

>SSRI Medication

>Subject: A Medscape article that might interest you.

>Date: 21 Feb 2002 13:49:55 -0500

>

>I thought you might be interested in this.

>

>ha! who are they kidding? this is a move toward 4th reichism. the bums.

>

>

>To access the article, click on this Web address, or cut and paste it into

>a browser window.

>

>This article notification service provided by http://www.medscape.com

>

>* Physician optimized MEDLINE

>* Free Online CME

>* 25+ medical specialty sites

>* 100+ online medical journals

>* Conference Coverage

>* Daily Medical News

>

>Free email is available to Medscape members -- the perfect solution for the

>mobile professional.

>

>

>

>

>

>

>

[Guest guest]

Dear ,

What is the title?

Suzy

>From: stinky72001@...

>Reply-SSRI medications

>SSRI Medication

>Subject: A Medscape article that might interest you.

>Date: 21 Feb 2002 13:49:55 -0500

>

>I thought you might be interested in this.

>

>ha! who are they kidding? this is a move toward 4th reichism. the bums.

>

>

>To access the article, click on this Web address, or cut and paste it into

>a browser window.

>

>This article notification service provided by http://www.medscape.com

>

>* Physician optimized MEDLINE

>* Free Online CME

>* 25+ medical specialty sites

>* 100+ online medical journals

>* Conference Coverage

>* Daily Medical News

>

>Free email is available to Medscape members -- the perfect solution for the

>mobile professional.

>

>

>

>

>

>

>

[Guest guest]

Dear Suzy,

I had to repost it - it's the one about the 10 million dollar wall

they want to build around the nih for security - no biggy - I guess I

must have been having a zoloft moment!

> Dear ,

>

> What is the title?

>

> Suzy

>

>

> >From: stinky72001@y...

> >Reply-SSRI medications@y...

> >SSRI Medication@y...

> >Subject: A Medscape article that might interest

you.

> >Date: 21 Feb 2002 13:49:55 -0500

> >

> >I thought you might be interested in this.

> >

> >ha! who are they kidding? this is a move toward 4th reichism. the

bums.

> >

> >

> >To access the article, click on this Web address, or cut and paste

it into

> >a browser window.

> >

> >This article notification service provided by

http://www.medscape.com

> >

> >* Physician optimized MEDLINE

> >* Free Online CME

> >* 25+ medical specialty sites

> >* 100+ online medical journals

> >* Conference Coverage

> >* Daily Medical News

> >

> >Free email is available to Medscape members -- the perfect solution

for the

> >mobile professional.

> >

> >

> >

> >

> >

> >

> >

[Guest guest]

Dear Suzy,

I had to repost it - it's the one about the 10 million dollar wall

they want to build around the nih for security - no biggy - I guess I

must have been having a zoloft moment!

> Dear ,

>

> What is the title?

>

> Suzy

>

>

> >From: stinky72001@y...

> >Reply-SSRI medications@y...

> >SSRI Medication@y...

> >Subject: A Medscape article that might interest

you.

> >Date: 21 Feb 2002 13:49:55 -0500

> >

> >I thought you might be interested in this.

> >

> >ha! who are they kidding? this is a move toward 4th reichism. the

bums.

> >

> >

> >To access the article, click on this Web address, or cut and paste

it into

> >a browser window.

> >

> >This article notification service provided by

http://www.medscape.com

> >

> >* Physician optimized MEDLINE

> >* Free Online CME

> >* 25+ medical specialty sites

> >* 100+ online medical journals

> >* Conference Coverage

> >* Daily Medical News

> >

> >Free email is available to Medscape members -- the perfect solution

for the

> >mobile professional.

> >

> >

> >

> >

> >

> >

> >

[Guest guest]

> I thought you might be interested in this.

>

Sorry, I thought that this would be copied when I forwarded it

Hopefully, this will work

September 21, 2002

Aventis Pasteur to Launch Preservative-Free Influenza Vaccine For

Infants

WASHINGTON (Reuters Health) Sept 12 - Aventis Pasteur Inc., a US

subsidiary of French drugmaker Aventis SA, said on Thursday that it

has received approval from the US Food and Drug Administration (FDA)

to market a preservative-free formulation of its influenza vaccine

Fluzone for infants ages 6 to 35 months.

According to the Swiftwater, Pennsylvania-based concern, this would

be the first preservative-free influenza vaccine approved for infant

administration. But due to the current manufacturing schedule,

Aventis Pasteur said only a limited quantity of pediatric vaccine

will be available for the 2002-2003 season.

Aventis, which supplies about 50% of the nation's flu vaccine, said

it developed the pediatric formulation to boost public confidence in

the immunization of young children. Fears regarding the use of

vaccines containing preservatives in infants have grown in the US

since the FDA revealed in 1999 that the amount of mercury intake for

some babies in their first six months might exceed limits set by the

US Environmental Protection Agency (EPA). Mercury is the main

ingredient in the vaccine preservative thimerosal.

The firm has the capacity to produce greater quantities of the

vaccine for the 2003-2004 season and will proceed to make more if the

US Centers for Disease Control and Prevention's Advisory Committee on

Immunization Practices (ACIP) strengthens its current recommendations

for the annual immunization of healthy children, Aventis said.

The ACIP currently is considering a plan to strengthen its present

recommendations to include annual immunizations of healthy children

aged 6 to 23 months.

For the 2002-2003 influenza season, Aventis said the infant vaccine

will be packaged in pre-filled syringes and launched in early to mid-

November.

[Guest guest]

what is the current statis for immunizations with mercury? I have

not been able to find a clear answer from a reliabe source. Does

anyone have a link to show what has been done, in US or by states?

I do see however that the state encouraging immunizations as a whole

are still in full force.

autiemom4

Autism Family Circle

http://autismfamilycircle.com

Autism Family Circle Group

autismfamilycircle

Autism Family Circle Chat House

http://pub90.ezboard.com/bautismfamilycirclechathouse

***New Listing for Autism Awareness Ribbon Pins at Ebay:

http://cgi.ebay.com/ws/eBayISAPI.dll?ViewItem & item=716249066

Autism Kansas Advocate Group

kansasautismadvoc/

> > I thought you might be interested in this.

> >

>

> Sorry, I thought that this would be copied when I forwarded it

>

> Hopefully, this will work

> September 21, 2002

>

>

> Aventis Pasteur to Launch Preservative-Free Influenza Vaccine For

> Infants

>

>

>

>

> WASHINGTON (Reuters Health) Sept 12 - Aventis Pasteur Inc., a US

> subsidiary of French drugmaker Aventis SA, said on Thursday that it

> has received approval from the US Food and Drug Administration

(FDA)

> to market a preservative-free formulation of its influenza vaccine

> Fluzone for infants ages 6 to 35 months.

> According to the Swiftwater, Pennsylvania-based concern, this would

> be the first preservative-free influenza vaccine approved for

infant

> administration. But due to the current manufacturing schedule,

> Aventis Pasteur said only a limited quantity of pediatric vaccine

> will be available for the 2002-2003 season.

>

> Aventis, which supplies about 50% of the nation's flu vaccine, said

> it developed the pediatric formulation to boost public confidence

in

> the immunization of young children. Fears regarding the use of

> vaccines containing preservatives in infants have grown in the US

> since the FDA revealed in 1999 that the amount of mercury intake

for

> some babies in their first six months might exceed limits set by

the

> US Environmental Protection Agency (EPA). Mercury is the main

> ingredient in the vaccine preservative thimerosal.

>

> The firm has the capacity to produce greater quantities of the

> vaccine for the 2003-2004 season and will proceed to make more if

the

> US Centers for Disease Control and Prevention's Advisory Committee

on

> Immunization Practices (ACIP) strengthens its current

recommendations

> for the annual immunization of healthy children, Aventis said.

>

> The ACIP currently is considering a plan to strengthen its present

> recommendations to include annual immunizations of healthy children

> aged 6 to 23 months.

>

> For the 2002-2003 influenza season, Aventis said the infant vaccine

> will be packaged in pre-filled syringes and launched in early to

mid-

> November.

[Guest guest]

You cannot access this article without a subscription.

> I thought members might be interested in this.

> http://www.medscape.com/viewarticle/484371?src=mp

> To access the article, click on this Web address, or cut and paste

it into a browser window.

>

> This article notification service provided by

http://www.medscape.com

>

> * Physician optimized MEDLINE

> * Free Online CME

> * 25+ medical specialty sites

> * 100+ online medical journals

> * Conference Coverage

> * Daily Medical News

>

> Free email is available to Medscape members -- the perfect solution

for the mobile professional.

[Guest guest]

Hello All,

This is an interesting look at " evidence-based " whatever...

C Simpson

A Medscape article that might interest you.

I thought you might be interested in this.

http://www.medscape.com/viewarticle/498489?src=mp

To access the article, click on this Web address, or cut and paste it

into a browser window.

This article notification service provided by http://www.medscape.com

* Physician optimized MEDLINE

* Free Online CME

* 25+ medical specialty sites

* 100+ online medical journals

* Conference Coverage

* Daily Medical News

Free email is available to Medscape members -- the perfect solution for

the mobile professional.

[Guest guest]

it is from me, nancie

A Medscape article that might interest you.

I thought you might be interested in this.

http://www.medscape.com/viewarticle/556136<http://www.medscape.com/viewarticle/5\

56136>

To access the article, click on this Web address, or cut and paste it into a

browser window.

This article notification service provided by

http://www.medscape.com<http://www.medscape.com/>

* Physician optimized MEDLINE

* Free Online CME

* 25+ medical specialty sites

* 100+ online medical journals

* Conference Coverage

* Daily Medical News

Free email is available to Medscape members -- the perfect solution for the

mobile professional.

[Guest guest]

----- Forwarded Message ----

From: " autumntwilight1981@... " <autumntwilight1981@...>

autumntwilight1981@...

Sent: Saturday, February 9, 2008 2:21:56 PM

Subject: A Medscape article that might interest you.

I thought you might be interested in this.

http://www.medscape.com/viewarticle/569918

To access the article, click on this Web address, or cut and paste it into a

browser window.

This article notification service provided by http://www.medscape.com

* Physician optimized MEDLINE

* Free Online CME

* 25+ medical specialty sites

* 100+ online medical journals

* Conference Coverage

* Daily Medical News

Free email is available to Medscape members -- the perfect solution for the

mobile professional.

[Guest guest]

Great... another way for them to mass vaccinate without informed consent or

even possibly patient knowledge of the procedure...

Cr

http://www.medscape.com/viewarticle/570056?sssdmh=dm1.336139 & src=nldne

To access the article, click on this Web address, or cut and paste it into a

browser window.

This article notification service provided by http://www.medscape.com

Aerosol Vaccination Shows Promise in Animal Study

Information from Industry

Assess clinically focused product information on Medscape.

Click Here for Product Infosites -- Information from Industry.

NEW YORK (Reuters Health) Feb 11 - In a study using poxvirus-based vaccine

vectors, a European research team shows that aerosol immunization is safe,

simple and immunogenic.

The researchers believe that the development of aerosol vaccines could play a

key role in combatting vaccine-preventable mucosally transmitted diseases, which

currently claim the lives of roughly 5 million people each year across the

globe.

As reported in the Proceedings of the National Academy of Sciences for February

12th, Dr. Jean-Pierre Kraehenbuhl, from the EuroVacc Foundation in Epalinges,

Switzerland, and colleagues examined the feasibility of aerosolized HIV and

human papillomavirus vaccines in non-human primates.

Using real-time scintigraphy, the researchers showed that the radiolabeled

vaccines consistently reached target areas in the respiratory tract. Moreover,

the vaccines appeared to be safe with no evidence of vaccine-associated

pathology, particularly in the lungs or the brain. Lastly, the vaccines were

immunogenic; in the case of the HIV vaccine, use of a prime/boost regimen

resulted in a long-lasting, HIV-specific immune response.

" Aerosol vaccination with (these poxvirus-based) vectored vaccines constitutes a

tool for large-scale vaccine efforts against mucosally transmitted pathogens, "

the investigators conclude.

Proc Natl Acad Sci USA 2008;105:2046-2051.

[Guest guest]

My opinion is this just proves that OB's are getting less and less patient.

More inductions on unripe cervixes and babies that aren't ready yet because

their Mom's gestate a little longer. It makes sense that a longer cervix might

take longer to progress than a shorter one. DUH!

---------------------------------------------------------------------

This activity is developed and funded by Medscape.

Long Cervix May Predict Need for Cesarean Delivery in Primiparous Women CME

News Author: Laurie Barclay, MD

CME Author: Désirée Lie, MD, MSEd

Complete author affiliations and disclosures, and other CME information, are

available at the end of this activity.

Release Date: March 26, 2008; Valid for credit through March 26, 2009

Credits Available

Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for physicians;

Family Physicians - up to 0.25 AAFP Prescribed credit(s) for physicians

All other healthcare professionals completing continuing education credit for

this activity will be issued a certificate of participation.

Physicians should only claim credit commensurate with the extent of their

participation in the activity.

To participate in this internet activity: (1) review the target audience,

learning objectives, and author disclosures; (2) study the education content;

(3) take the post-test and/or complete the evaluation; (4) view/print

certificate View details.

Learning Objectives

Upon completion of this activity, participants will be able to:

Describe associations of a long cervix during pregnancy in primiparous women.

Describe the association between cervical length and cesarean delivery in

primiparous women.

Authors and Disclosures

Laurie Barclay, MD

Disclosure: Laurie Barclay, MD, has disclosed no relevant financial

relationships.

Désirée Lie, MD, MSEd

Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial

relationships.

Brande

Disclosure: Brande has disclosed no relevant financial

information.

March 26, 2008 — A long cervix in midpregnancy may predict the need for a

cesarean delivery at term in primiparous women, according to the results of a

study in the March 27 issue of the New England Journal of Medicine.

" Physiological and biochemical studies suggest that normal parturition at term

is dependent on programmed development of the uterus in early pregnancy, " write

Gordon C.S. , MD, PhD, from Cambridge University, Cambridge, United

Kingdom, and colleagues from the Fetal Medicine Foundation Second Trimester

Screening Group. " It is recognized that a short cervix in mid-pregnancy is

associated with an increased risk of spontaneous preterm birth. We hypothesized

that a long cervix in mid-pregnancy would be associated with an increased risk

of cesarean delivery during labor at term. "

The investigators studied 27,472 primiparous women with a cervical length of at

least 16 mm at a median of 23 weeks of gestation who delivered a live infant in

labor at term.

The rate of cesarean delivery at term was lowest (16.0%) for women with

midpregnancy cervical length in the lowest quartile (16 - 30 mm). This rate

increased significantly for women in the second quartile (18.4%; 31 - 35 mm),

third quartile (21.7%; 36 - 39 mm), and fourth quartile (25.7%; 40 - 67 mm; P <

..001 for trend).

Compared with women in the first quartile, women in the fourth quartile had an

odds ratio (OR) for cesarean delivery of 1.81 (95% confidence interval [CI],

1.66 - 1.97). After adjustment for maternal age, body mass index (BMI), smoking

status, race or ethnic group, gestational age at birth, spontaneous or induced

labor, birthweight percentile, and hospital of delivery, the OR was 1.68 (95%

CI, 1.53 - 1.84; P < .001).

" The increased risk of cesarean delivery was attributable to procedures

performed for poor progress in labor, " the study authors write. " The cervical

length at mid-pregnancy is an independent predictor of the risk of cesarean

delivery at term in primiparous women. "

Limitations of the study include lack of serial measurement of cervical length

throughout pregnancy, secondary analysis of data obtained for other purposes,

indication for cesarean delivery based only on the computerized delivery record,

and possible residual confounding.

" Poor progress during labor at term is the most common indication for primary

cesarean section and, hence, an important determinant of overall rates of

cesarean section, " the study authors conclude. " Our finding that a long cervix

in mid-pregnancy is predictive of cesarean section during labor at term suggests

that poor progress during labor in women who deliver at term may be related to

dysfunctional development of the uterus at much earlier stages of pregnancy. "

The Fetal Medicine Foundation supported this study. The study authors have

disclosed no relevant financial relationships.

N Engl J Med. 2008;358:1346-1353.

Learning Objectives for This Educational Activity

Upon completion of this activity, participants will be able to:

Describe associations of a long cervix during pregnancy in primiparous women.

Describe the association between cervical length and cesarean delivery in

primiparous women.

Clinical Context

Rates of cesarean delivery have increased dramatically in the developed world,

mainly because of a decreasing rate of vaginal delivery after cesarean delivery.

Also, the major cause of cesarean delivery in primiparous women has been

identified as failure to progress during labor ( " dystocia " ). Although risk

factors for failure to progress have been identified as advanced maternal age,

obesity, and postterm delivery, the underlying biological mechanisms are poorly

understood. A short cervix has been reported as a cause of preterm delivery, and

the study authors hypothesized that a long cervix may contribute to higher risk

for delivery by cesarean delivery.

This is a secondary analysis of a study conducted at 8 hospitals around London

between 1998 and 2004 in the United Kingdom on the association between a short

cervix, as measured by ultrasonography, and preterm delivery to determine if a

long cervix was associated with higher rates of cesarean delivery.

Study Highlights

Included were primiparous women who had a cervical length measurement and who

delivered at term.

Excluded were women with stillbirth or therapeutic abortion whose cervical

length was 15 mm or less (short cervix) and whose infants were delivered by

prelabor cesarean delivery.

In the primary study, women with a short cervix were offered cervical cerclage

or vaginal administration of progesterone, but these women were excluded from

the current study.

Women underwent vaginal ultrasonography, including cervical length assessment

and uterine-artery Doppler flow velocimetry, between 22 and 24 weeks' gestation.

Cervical length was determined by ultrasonographers trained in these methods,

and quality control across sites was performed on a regular basis.

Clinical history and obstetric histories were obtained by face-to-face

interviews with the mothers with use of a structured questionnaire.

The outcome of each pregnancy was obtained from computerized delivery records

and included mode of delivery, gestational age, whether the patient was in

labor, and indications for operative delivery.

The primary outcome was cesarean delivery performed during labor at term and

indications for cesarean delivery.

The study group consisted of 27,472 women representing 90.2% of all eligible

primiparous women screened.

The median gestational age at the time of measurement of cervical length was 23

weeks.

Cervical length at 23 weeks was positively associated with increasing maternal

age, nonsmoking (vs smoking), increasing BMI, white race, increasing gestational

age at birth, induced (vs spontaneous) labor, and increasing birthweight

percentile.

A total of 5542 women underwent cesarean delivery; in 4615 (83.3%) of these

procedures, failure to progress in labor was included in the list of

indications.

The rate of cesarean delivery was lowest among women with cervical length at 23

weeks in the lowest quartile (16.0%) and was significantly higher in the second

quartile (18.4%), third quartile (21.7%), and fourth quartile (25.7%; P < .001

for trend).

The risk for cesarean delivery increased with increasing absolute values of

midpregnancy cervical length.

The rate of cesarean delivery started to increase at a cervical length of 25 mm

and plateaued at a cervical length of 50 mm, doubling across the range of

observed values.

Adjustment for covariates of age, BMI, smoking status, gestational age, age at

birth, birthweight, and location did not eliminate the significant association.

The OR for cesarean delivery in the fourth vs the first quartile was 1.81 (95%

CI,

1.66 - 1.97); after adjustment, the OR was 1.68 (P < .001).

There were no significant interactions between cervical length and any maternal

characteristics in predicting the risk for cesarean delivery.

The attributable fraction for cesarean delivery associated with the upper 3

quartiles of cervical length was 20.5%; after adjustment for maternal

characteristics, it was 17.2%.

The authors concluded that the risk for cesarean delivery was attributable to

cervical length in midpregnancy and that a long cervix in midpregnancy was

associated with failure to progress during labor.

They suggested that poor progress during labor may be related to dysfunctional

development of the uterus at much earlier stages of pregnancy.

Pearls for Practice

Cervical length at 23 weeks' gestation is associated with increasing maternal

age, nonsmoking (vs smoking), increasing BMI, white race, increasing gestational

age at birth, induced (vs spontaneous) labor, and increasing birthweight

percentile.

Greater cervical length in midpregnancy is associated with a higher risk for

cesarean delivery and failure to progress in labor.

According to the study by and colleagues, cervical length during

midpregnancy is least likely to be associated with which of the following

variables?

Maternal smoking

Older age

Higher BMI

Increasing birthweight

According to the study by and colleagues, the adjusted OR for cesarean

delivery for a woman with cervical length in the fourth vs the first quartile

during midpregnancy is best described by which of the following?

1.0

1.2

1.8

2.3

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online

educational activity. For information on applicability and acceptance of

continuing education credit for this activity, please consult your professional

licensing board.

This activity is designed to be completed within the time designated on the

title page; physicians should claim only those credits that reflect the time

actually spent in the activity. To successfully earn credit, participants must

complete the activity online during the valid credit period that is noted on the

title page.

FOLLOW THESE STEPS TO EARN CME/CE CREDIT*:

Read the target audience, learning objectives, and author disclosures.

Study the educational content online or printed out.

Online, choose the best answer to each test question. To receive a certificate,

you must receive a passing score as designated at the top of the test. Medscape

encourages you to complete the Activity Evaluation to provide feedback for

future programming.

You may now view or print the certificate from your CME/CE Tracker. You may

print the certificate but you cannot alter it. Credits will be tallied in your

CME/CE Tracker and archived for 5 years; at any point within this time period

you can print out the tally as well as the certificates by accessing " Edit Your

Profile " at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

Target Audience

This article is intended for primary care clinicians, obstetricians, and other

specialists who care for pregnant women.

Goal

The goal of this activity is to provide medical news to primary care clinicians

and other healthcare professionals in order to enhance patient care.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical

Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA

Category 1 Credit(s)™. Physicians should only claim credit commensurate with the

extent of their participation in the activity. Medscape Medical News has been

reviewed and is acceptable for up to 300 Prescribed credits by the American

Academy of Family Physicians. AAFP accreditation begins 09/01/07. Term of

approval is for 1 year from this date. This activity is approved for 0.25

Prescribed credits. Credit may be claimed for 1 year from the date of this

activity. AAFP credit is subject to change based on topic selection throughout

the accreditation year.

AAFP Accreditation Questions

For questions regarding the content of this activity, contact the accredited

provider for this CME/CE activity: CME@.... For technical assistance,

contact CME@....

Authors and Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who

is in a position to control the content of an education activity to disclose all

relevant financial relationships with any commercial interest. The ACCME defines

" relevant financial relationships " as financial relationships in any amount,

occurring within the past 12 months, including financial relationships of a

spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or

off-label uses of products regulated by the US Food and Drug Administration, at

first mention and where appropriate in the content.

News Author

Laurie Barclay, MD

is a freelance reviewer and writer for Medscape.

Disclosure: Laurie Barclay, MD, has disclosed no relevant financial

relationships.

CME Author

Désirée Lie, MD, MSEd

Clinical Professor, Family Medicine, University of California, Orange; Director,

Division of Faculty Development, UCI Medical Center, Orange, California

Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial

relationships.

Brande

is the News CME editor for Medscape Medical News.

Disclosure: Brande has disclosed no relevant financial

information.

Medscape Medical News 2008. ©2008 Medscape

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape

or companies that support educational programming on www.medscape.com. These

materials may discuss therapeutic products that have not been approved by the US

Food and Drug Administration and off-label uses of approved products. A

qualified healthcare professional should be consulted before using any

therapeutic product discussed. Readers should verify all information and data

before treating patients or employing any therapies described in this

educational activity.

Registration for CME credit and the post test must be completed online.

To access the activity Post Test, please go to:

http://www.medscape.com/viewarticle/571990

----- Forwarded Message ----

From: " autumntwilight1981@... " <autumntwilight1981@...>

autumntwilight1981@...

Sent: Thursday, March 27, 2008 10:57:14 PM

Subject: A Medscape article that might interest you.

I thought you might be interested in this.

http://www.medscape.com/viewarticle/571990?sssdmh=dm1.342403 & src=nldne

To access the article, click on this Web address, or cut and paste it into a

browser window.

This article notification service provided by http://www.medscape.com

* Physician optimized MEDLINE

* Free Online CME

* 25+ medical specialty sites

* 100+ online medical journals

* Conference Coverage

* Daily Medical News

Free email is available to Medscape members -- the perfect solution for the

mobile professional.

[Guest guest]

This discusses PCOD aka polycystic ovarian disease.

-- A Medscape article that might interest you.

I thought you might be interested in this.

http://www.medscape.com/viewarticle/466573_2

To access the article, click on this Web address, or cut and paste it into a

browser window.

This article notification service provided by http://www.medscape.com

* Physician optimized MEDLINE

* Free Online CME

* 25+ medical specialty sites

* 100+ online medical journals

* Conference Coverage

* Daily Medical News

Free email is available to Medscape members -- the perfect solution for the

mobile professional.

[Guest guest]

Hi . I believe that it is a credible article. I am pleased that it is a neurologist making the statement. The findings accurately mirror my own numbers from the 228 self-reported cases of adverse reactions that I am currently subjecting to analysis, from the global e-petition. In 228 cases of a reaction to statins, 15 people are reporting ALS or ALS-like symptoms after taking statins. Dr reports 14 cases out of 31 with ALS, who were taking statins and the total; number is 240 cases with ALS. There is a consonance between these numbers that I find both compelling and fear-inducing. JeffOn 30 Sep 2008, at 23:11, dpmanzari@... wrote:I will be interested in each of your responses to this article.http://www.medscape.com/viewarticle/581181?sssdmh=dm1.389712 & src=nldneTo access the article, click on this Web address, or cut and paste it into a browser window.This article notification service provided by http://www.medscape.com* Physician optimized MEDLINE* Free Online CME* 25+ medical specialty sites* 100+ online medical journals* Conference Coverage* Daily Medical NewsFree email is available to Medscape members -- the perfect solution for the mobile professional.

[Guest guest]

I thought you might be interested in this. It is about pediatric fungal

treatment.

http://www.medscape.com/viewarticle/585106_4

To access the article, click on this Web address, or cut and paste it into a

browser window.

This article notification service provided by http://www.medscape.com

* Physician optimized MEDLINE

* Free Online CME

* 25+ medical specialty sites

* 100+ online medical journals

* Conference Coverage

* Daily Medical News

Free email is available to Medscape members -- the perfect solution for the

mobile professional.